News

Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.

Findings from the TAC ANRS 12311 trial revealed the success of tailored treatment combinations to the specific genotype of HCV to optimize efficacy and minimize adverse effects.

HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.

With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.

In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated Clostridioides difficile infections.

Jerry Krishnan, MD, PhD, working with NASEM, examines the multifaceted challenges of defining Long COVID as they introduce a unified definition for this persistent condition.

Study reveals an increase in hospital admissions and the need for advanced respiratory support, particularly among older, healthier children.

The state's attorney general filed the lawsuit against Pfizer for its ‘misleading statements’ about the vaccine.

While the global clinical pipeline for antibacterial treatments displays notable activity, it remains inadequate to address the challenges of antimicrobial resistance.

Tailored for adults, V116's effectiveness covers serotypes linked to 84% of invasive pneumococcal disease in those 50+, outperforming existing vaccines in immune response rates.

Bearded dragon pets carrying this illness and infecting their loving caregivers create a significant public health concern.

Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome (STSS), a severe and often fatal bacterial infection.

New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.

Experts emphasize prevalent waterborne illnesses and offer preventive advice for the summer season.

In response to evolving data on SARS-CoV-2 strains and rising COVID-19 cases, the FDA advises vaccine manufacturers to explore incorporating the KP2 strain into the upcoming 2024-2025 COVID-19 vaccine formula.

Overcoming “RSV identity crisis,” Moderna announced data for its investigational mRNA-1083 vaccine, BWC0977 effort to target drug-resistant pathogens, and more this week from Contagion.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.

Leveraging Evie Ring technology, the collaboration seeks to enhance understanding and develop strategies for managing these illnesses.

A recently published secondary analysis sought to evaluate the risk of MACE in those patients who received one or two doses of the COVID-19 following acute coronary syndromes.

The latest data from the Gonococcal Antimicrobial Susceptibility Surveillance, calls for updated treatment protocols and intensified surveillance measures to address this escalating concern effectively.

A study points to inpatients who were 50 years and older with the respiratory illness suffering from heart-related complications with the largest number of them having acute heart failure. 

With no observed mortality or adverse outcomes, this research sheds light on effective treatments for combating the pandemic in younger populations.

BWC0977 has strong potential to effectively target the priority pathogens needed to address public health concerns.

In the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.

Our experts discuss the potential subgroups who might benefit from the vaccines and their safety profiles.

In part 2 of a 4-part series, clinicians discuss the efficacy, and the mechanism of action of the approved RSV vaccines, including the newly approved Moderna vaccine, mRNA 1345 (mRESVIA).

This is the first in a series of discussions between medical peers around RSV vaccines and specifically the newly approved Moderna RSV vaccine for seniors.

Brii Biosciences presented new data from Phase 2 trials for chronic hepatitis B at EASL Congress 2024, revealing insights into the efficacy of BRII-179 as botha combined therapy and an additional treatment.

Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offering insights into microbiota alteration and prospects for management.